Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test by year’s end.
May 26, 2026 06:57 AM EDT
R&DCell/Gene Tx
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
Reynald Castaneda
Deputy Editor
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve
Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L
So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia
Gene-editing drugs are opening a new frontier in medicine
One dose of gene-editing drug cut bad cholesterol 62% for months in small trial
PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
Pharmalittle: We're reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a…
Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of…
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects…
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.
Tweaked lipid nanoparticle delivery system showed early safety
